Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pergoveris start day 1 versus delayed Pergoveris after GONAL-f in women aged 36-40 undergoing ART
2010-023534-23Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of luteinizing hormone and follitropin alfa in female infertility and infertility (2 arms), sponsored by Merck Serono. Primary endpoint: Total number of oocytes retrieved per subject following ovarian stimulation. Started Jan 2011; status: completed.
02
Drugs
luteinizing hormonefollitropin alfa
03
Conditions
female infertilityinfertility
Beyond the preview
Go deeper on 2010-023534-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023534-23.